3D printers next big industrial thing
Materialise incorporates nearly 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry.
According to Materialise,” Let’s discuss ways how we can empower people to design, collaborate, build, and fabricate in more sustainable ways, while reducing waste, saving money, and staying competitive. At the end of the second quarter of 2019, the total commitment of lease assets and liabilities amounted to 5,050 kEUR. Our Adjusted EBITDA for the second quarter of 2019 was affected positively by the new standard as a result of the rental payments decrease of 644 kEUR; however, our operating profit was impacted by only 52 kEUR as depreciation expenses increased by 593 kEUR.
Materialise, Will acquire a mix of existing and new shares bringing its total shareholding to 75%, with the founding shareholders retaining the remaining 25%. All shares will be fully paid for in cash at the closing, which is expected to take place during the week of August 5, 2019.”
According to Materialise reports the Second quarter and now, 2019 Results, Executive Chairman Peter Leys commented, “In spite of a macro-economic environment that continues to be challenging, Materialise reported another quarter of top-line growth. This was mainly driven by Materialise Medical, which continued to perform strongly with solid revenue growth and EBITDA performance, and also by Materialise Manufacturing, which realized a double-digit EBITDA margin and grew its revenues for the third consecutive quarter.
This quarter, the contribution by Materialise Software to our revenue growth and Adjusted EBITDA margin was below our expectations as a number of sales were pushed out to the second half of the year. Our outlook for 2019 remains within our previous guidance range, with our results now including expected contributions from our August acquisition of a 75% stake in Engimplan.
This investment, which will enable us to introduce the benefits of Materialise’s patient-specific 3D printing implants and expertise to the fast-growing Brazil market, is part of our strategy to accelerate our growing presence in the additive manufacturing ecosystem through carefully selected acquisitions and partnerships.”
According to Dr. Alex Morgan, Principal at Khosla Ventures and Dr. Melanie Matheu, Prellis Biologics’ co-founder and CEO, “Regenerative medicine has made enormous leaps in recent decades. However, to create complete organs, we need to build higher-order structures like the vascular system. Prellis’ optical technology provides the scaffolding necessary to engineer these larger masses of tissues. With our investment in Prellis, we’re supporting an initiative that will ultimately produce a functioning lobe of the lung, or even a kidney, to be used in addressing an enormous unmet global need.
The human tissue engineering is the ability to build complex tissues with working vascular systems. The future of regenerative medicine revolves around harnessing the power of our own cells as therapeutics and building the tissues to keep them alive. Khosla Ventures is the perfect investor to support our merging of deep tech and cutting-edge regenerative medicine. With this technology in hand, we can begin to ask questions about real 3D cell biology that have never been asked before.”